Medtronic will link with Apollo Hospitals Enterprise--one of India's largest healthcare providers--to develop a portable kidney dialysis system. The project represents the Minnesota device giant's first foray into hemodialysis and yet another diversification move for the company.
Drugmakers weren't exactly thrilled last year when Indian ministers nearly quintupled the list of drugs subject to government price controls. As it turns out, neither were bulk buyers of those products. GlaxoSmithKline is now feeling the effects of their discontent, with buyers' protests reportedly hurting the British drugmaker's sales.
Late-phase data has tempered expectations for GlaxoSmithKline's malaria vaccine. Yet while the vaccine prevents fewer cases than hoped and immunity wanes, it still has the potential to cut incidence of disease. Glaxo is readying for a regulatory submission. A malaria vaccine could arrive in 2015.
Syngene, the CRO arm of Indian biotech giant Biocon, is poised to swell about 20% a year, CEO Kiran Mazumdar-Shaw said, making it the continent's fastest-growing service provider.
Fresh off making its U.S. landfall, British CRO TranScrip Partners has expanded into Hong Kong, bringing its development and marketing services to Asia.
Out of 14 multinational med tech companies with beachheads in China, Medtronic is best positioned to take advanced of the country's expected surge in healthcare spending, according to a new analyst report. With China spending billions of dollars to modernize its healthcare system, Morningstar concluded in its latest Healthcare Observer that the Minnesota device giant has taken the strongest steps to get its devices and med tech products into the country and build a distribution network to get them to hospitals and patients.
Meeting next year's minimum revenue goal of $20 billion will be "challenging," Eli Lilly says, and analysts are already speculating about "savage" cost cuts if R&D doesn't come through as Lilly hopes.
Pharma may not have expected a Chinese Inquisition, but that's what pharma is getting. As the Wall Street Journal reports, China's anti-corruption drive is taking a page not only from Mao's book, but from medieval church enforcers.
Western drugmakers are looking to the Persian Gulf, Middle East and Africa for the growth they aren't finding in their usual stomping grounds. Now Merck is partnering to build an insulin plant in Bahrain.
On the path into emerging markets, drugmakers have stumbled across a thorny regulatory bush here, a pricing sinkhole there--not to mention a couple of big bad wolves in the form of Chinese investigators and Indian patent police. But Sanofi CEO Christopher Viehbacher figures that, whatever the obstacles, the journey will pay off.